ID   CHST2_HUMAN             Reviewed;         530 AA.
AC   Q9Y4C5; D3DNG5; Q2M370; Q9GZN5; Q9UED5; Q9Y6F2;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 2.
DT   10-MAY-2017, entry version 129.
DE   RecName: Full=Carbohydrate sulfotransferase 2;
DE            EC=2.8.2.-;
DE   AltName: Full=Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 2;
DE            Short=GST-2;
DE   AltName: Full=N-acetylglucosamine 6-O-sulfotransferase 1;
DE            Short=GlcNAc6ST-1;
DE            Short=Gn6ST-1;
GN   Name=CHST2; Synonyms=GN6ST;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, ALTERNATIVE
RP   INITIATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9722682; DOI=10.1093/oxfordjournals.jbchem.a022164;
RA   Uchimura K., Muramatsu H., Kaname T., Ogawa H., Yamakawa T.,
RA   Fan Q.-W., Mitsuoka C., Kannagi R., Habuchi O., Yokoyama I.,
RA   Yamamura K., Ozaki T., Nakagawara A., Kadomatsu K., Muramatsu T.;
RT   "Human N-acetylglucosamine-6-O-sulfotransferase involved in the
RT   biosynthesis of 6-sulfo sialyl Lewis X: molecular cloning, chromosomal
RT   mapping, and expression in various organs and tumor cells.";
RL   J. Biochem. 124:670-678(1998).
RN   [2]
RP   SEQUENCE REVISION.
RA   Uchimura K., Muramatsu H., Muramatsu T.;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=10049591; DOI=10.1006/geno.1998.5653;
RA   Li X., Tedder T.F.;
RT   "CHST1 and CHST2 sulfotransferases expressed by human vascular
RT   endothelial cells: cDNA cloning, expression, and chromosomal
RT   localization.";
RL   Genomics 55:345-347(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=11042394; DOI=10.1016/S0304-4165(00)00136-7;
RA   Sakaguchi H., Kitagawa H., Sugahara K.;
RT   "Functional expression and genomic structure of human N-
RT   acetylglucosamine-6-O-sulfotransferase that transfers sulfate to b-N-
RT   acetylglucosamine at the nonreducing end of an N-acetyllactosamine
RT   sequence.";
RL   Biochim. Biophys. Acta 1523:269-276(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11310842;
RA   Li X., Tu L., Murphy P.G., Kadono T., Steeber D.A., Tedder T.F.;
RT   "CHST1 and CHST2 sulfotransferase expression by vascular endothelial
RT   cells regulates shear-resistant leukocyte rolling via L-selectin.";
RL   J. Leukoc. Biol. 69:565-574(2001).
RN   [8]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ARG-174; ARG-296;
RP   LYS-304; ARG-332 AND ARG-341.
RX   PubMed=12501187; DOI=10.1021/bi0269557;
RA   Grunwell J.R., Rath V.L., Rasmussen J., Cabrilo Z., Bertozzi C.R.;
RT   "Characterization and mutagenesis of Gal/GlcNAc-6-O-
RT   sulfotransferases.";
RL   Biochemistry 41:15590-15600(2002).
RN   [9]
RP   SUBSTRATE SPECIFICITY.
RX   PubMed=11726653; DOI=10.1074/jbc.M106587200;
RA   Uchimura K., El-Fasakhany F.M., Hori M., Hemmerich S., Blink S.E.,
RA   Kansas G.S., Kanamori A., Kumamoto K., Kannagi R., Muramatsu T.;
RT   "Specificities of N-acetylglucosamine-6-O-sulfotransferases in
RT   relation to L-selectin ligand synthesis and tumor-associated enzyme
RT   expression.";
RL   J. Biol. Chem. 277:3979-3984(2002).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12855678; DOI=10.1074/jbc.M304928200;
RA   de Graffenried C.L., Bertozzi C.R.;
RT   "Golgi localization of carbohydrate sulfotransferases is a determinant
RT   of L-selectin ligand biosynthesis.";
RL   J. Biol. Chem. 278:40282-40295(2003).
RN   [11]
RP   MUTAGENESIS OF LYS-518; ASP-519; LEU-520; SER-521; LYS-522; THR-523;
RP   LEU-524; LEU-525; ARG-526; LYS-527; PRO-528; ARG-529 AND LEU-530.
RX   PubMed=15632306; DOI=10.1093/jb/mvh162;
RA   Chen L., Ichihara-Tanaka K., Muramatsu T.;
RT   "Role of the carboxyl-terminal region in the activity of N-
RT   acetylglucosamine 6-o-sulfotransferase-1.";
RL   J. Biochem. 136:659-664(2004).
RN   [12]
RP   SUBUNIT, AND MUTAGENESIS OF CYS-59 AND CYS-86.
RX   PubMed=15220337; DOI=10.1074/jbc.M405709200;
RA   de Graffenried C.L., Bertozzi C.R.;
RT   "The stem region of the sulfotransferase GlcNAc6ST-1 is a determinant
RT   of substrate specificity.";
RL   J. Biol. Chem. 279:40035-40043(2004).
RN   [13]
RP   GLYCOSYLATION AT ASN-243; ASN-457 AND ASN-475, LACK OF GLYCOSYLATION
RP   AT ASN-152, AND MUTAGENESIS OF ASN-457 AND ASN-475.
RX   PubMed=19571171; DOI=10.1093/glycob/cwp092;
RA   Desko M.M., Gross D.A., Kohler J.J.;
RT   "Effects of N-glycosylation on the activity and localization of
RT   GlcNAc-6-sulfotransferase 1.";
RL   Glycobiology 19:1068-1077(2009).
RN   [14]
RP   SUBCELLULAR LOCATION, SUBUNIT, AND ALTERNATIVE INITIATION.
RX   PubMed=22260995; DOI=10.1369/0022155412437613;
RA   Fujiwara M., Kobayashi M., Hoshino H., Uchimura K., Nakada T.,
RA   Masumoto J., Sakai Y., Fukuda M., Nakayama J.;
RT   "Expression of long-form N-acetylglucosamine-6-O-sulfotransferase 1 in
RT   human high endothelial venules.";
RL   J. Histochem. Cytochem. 60:397-407(2012).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl
CC       sulfate (PAPS) as sulfonate donor to catalyze the transfer of
CC       sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc)
CC       residues within keratan-like structures on N-linked glycans and
CC       within mucin-associated glycans that can ultimately serve as SELL
CC       ligands. SELL ligands are present in high endothelial cells (HEVs)
CC       and play a central role in lymphocyte homing at sites of
CC       inflammation. Participates in biosynthesis of the SELL ligand
CC       sialyl 6-sulfo Lewis X and in lymphocyte homing to Peyer patches.
CC       Has no activity toward O-linked sugars. Its substrate specificity
CC       may be influenced by its subcellular location. Sulfates GlcNAc
CC       residues at terminal, non-reducing ends of oligosaccharide chains.
CC       {ECO:0000269|PubMed:11042394}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.9 uM for PAPS {ECO:0000269|PubMed:12501187};
CC         KM=1.4 mM for BetaBnO-GlcNAc {ECO:0000269|PubMed:12501187};
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Homodimerization is not
CC       essential for enzyme activity. {ECO:0000269|PubMed:15220337,
CC       ECO:0000269|PubMed:22260995}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network
CC       membrane {ECO:0000269|PubMed:12855678,
CC       ECO:0000269|PubMed:22260995}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12855678, ECO:0000269|PubMed:22260995}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y4C5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y4C5-2; Sequence=VSP_018887;
CC         Note=Higher levels of expression compared to isoform 1 when
CC         expressed in HeLa cells. Exhibits similar intracellular
CC         GlcNAc-6-O-sulfation activity.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in bone
CC       marrow, peripheral blood leukocytes, spleen, brain, spinal cord,
CC       ovary and placenta. Expressed by high endothelial cells (HEVs) and
CC       leukocytes. {ECO:0000269|PubMed:10049591,
CC       ECO:0000269|PubMed:11310842, ECO:0000269|PubMed:9722682}.
CC   -!- INDUCTION: Up-regulated upon cytokine activation.
CC       {ECO:0000269|PubMed:11310842}.
CC   -!- PTM: Glycosylation at Asn-475 is required for catalytic activity.
CC       {ECO:0000269|PubMed:19571171}.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family.
CC       Gal/GlcNAc/GalNAc subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA34265.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB16886.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB16887.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB014679; BAA34265.2; ALT_INIT; mRNA.
DR   EMBL; AB014680; BAA34266.2; -; mRNA.
DR   EMBL; AF083066; AAD20981.1; -; mRNA.
DR   EMBL; AB021124; BAB16886.1; ALT_INIT; mRNA.
DR   EMBL; AB021125; BAB16887.1; ALT_INIT; Genomic_DNA.
DR   EMBL; CH471052; EAW78952.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78953.1; -; Genomic_DNA.
DR   EMBL; BC105010; AAI05011.1; -; mRNA.
DR   EMBL; BC105012; AAI05013.1; -; mRNA.
DR   CCDS; CCDS3129.1; -. [Q9Y4C5-1]
DR   RefSeq; NP_004258.2; NM_004267.4. [Q9Y4C5-1]
DR   UniGene; Hs.529249; -.
DR   UniGene; Hs.8786; -.
DR   ProteinModelPortal; Q9Y4C5; -.
DR   SMR; Q9Y4C5; -.
DR   STRING; 9606.ENSP00000307911; -.
DR   iPTMnet; Q9Y4C5; -.
DR   PhosphoSitePlus; Q9Y4C5; -.
DR   BioMuta; CHST2; -.
DR   DMDM; 61212252; -.
DR   PaxDb; Q9Y4C5; -.
DR   PeptideAtlas; Q9Y4C5; -.
DR   PRIDE; Q9Y4C5; -.
DR   DNASU; 9435; -.
DR   Ensembl; ENST00000309575; ENSP00000307911; ENSG00000175040. [Q9Y4C5-1]
DR   GeneID; 9435; -.
DR   KEGG; hsa:9435; -.
DR   CTD; 9435; -.
DR   DisGeNET; 9435; -.
DR   GeneCards; CHST2; -.
DR   HGNC; HGNC:1970; CHST2.
DR   HPA; HPA013620; -.
DR   MalaCards; CHST2; -.
DR   MIM; 603798; gene.
DR   neXtProt; NX_Q9Y4C5; -.
DR   OpenTargets; ENSG00000175040; -.
DR   PharmGKB; PA26502; -.
DR   eggNOG; ENOG410IIA6; Eukaryota.
DR   eggNOG; ENOG4111DKG; LUCA.
DR   GeneTree; ENSGT00530000062902; -.
DR   HOGENOM; HOG000261614; -.
DR   HOVERGEN; HBG050949; -.
DR   InParanoid; Q9Y4C5; -.
DR   KO; K04745; -.
DR   OMA; MGGPADY; -.
DR   OrthoDB; EOG091G0V3Y; -.
DR   PhylomeDB; Q9Y4C5; -.
DR   TreeFam; TF342871; -.
DR   Reactome; R-HSA-2022854; Keratan sulfate biosynthesis.
DR   SABIO-RK; Q9Y4C5; -.
DR   ChiTaRS; CHST2; human.
DR   GeneWiki; CHST2; -.
DR   GenomeRNAi; 9435; -.
DR   PRO; PR:Q9Y4C5; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000175040; -.
DR   CleanEx; HS_CHST2; -.
DR   ExpressionAtlas; Q9Y4C5; baseline and differential.
DR   Genevisible; Q9Y4C5; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0031228; C:intrinsic component of Golgi membrane; NAS:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0001517; F:N-acetylglucosamine 6-O-sulfotransferase activity; IDA:UniProtKB.
DR   GO; GO:0008146; F:sulfotransferase activity; TAS:ProtInc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0018146; P:keratan sulfate biosynthetic process; TAS:Reactome.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0006044; P:N-acetylglucosamine metabolic process; IDA:UniProtKB.
DR   GO; GO:0006790; P:sulfur compound metabolic process; IDA:UniProtKB.
DR   InterPro; IPR016469; Carbohydrate_sulfotransferase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   PIRSF; PIRSF005883; Carbohydrate_sulfotransferase; 1.
DR   SUPFAM; SSF52540; SSF52540; 3.
PE   1: Evidence at protein level;
KW   Alternative initiation; Carbohydrate metabolism; Complete proteome;
KW   Disulfide bond; Glycoprotein; Golgi apparatus; Inflammatory response;
KW   Membrane; Reference proteome; Signal-anchor; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1    530       Carbohydrate sulfotransferase 2.
FT                                /FTId=PRO_0000085186.
FT   TOPO_DOM      1     54       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     55     75       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     76    530       Lumenal. {ECO:0000255}.
FT   NP_BIND     173    179       PAPS. {ECO:0000305}.
FT   NP_BIND     332    340       PAPS. {ECO:0000305}.
FT   SITE        152    152       Not glycosylated.
FT                                {ECO:0000269|PubMed:19571171}.
FT   CARBOHYD    243    243       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19571171}.
FT   CARBOHYD    457    457       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19571171}.
FT   CARBOHYD    475    475       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19571171}.
FT   VAR_SEQ       1     47       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_018887.
FT   MUTAGEN      59     59       C->S: Does not affect homodimerization.
FT                                Abolishes homodimerization but not enzyme
FT                                activity; when associated with S-39.
FT                                {ECO:0000269|PubMed:15220337}.
FT   MUTAGEN      86     86       C->S: Induces migration in both
FT                                homodimeric and monomeric forms.
FT                                Abolishes homodimerization but not enzyme
FT                                activity; when associated with S-12.
FT                                {ECO:0000269|PubMed:15220337}.
FT   MUTAGEN     174    174       R->A: Induces a strong decrease in enzyme
FT                                activity. {ECO:0000269|PubMed:12501187}.
FT   MUTAGEN     296    296       R->A: Induces a strong decrease in enzyme
FT                                activity. {ECO:0000269|PubMed:12501187}.
FT   MUTAGEN     304    304       K->A: Loss of function.
FT                                {ECO:0000269|PubMed:12501187}.
FT   MUTAGEN     332    332       R->A: Loss of function.
FT                                {ECO:0000269|PubMed:12501187}.
FT   MUTAGEN     341    341       R->A: Induces a strong decrease in enzyme
FT                                activity. {ECO:0000269|PubMed:12501187}.
FT   MUTAGEN     457    457       N->A: Reduced localization in the Golgi.
FT                                {ECO:0000269|PubMed:19571171}.
FT   MUTAGEN     475    475       N->A: Unable to sulfate the sialyl Lewis
FT                                X tetrasaccharide.
FT                                {ECO:0000269|PubMed:19571171}.
FT   MUTAGEN     518    518       K->A: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     519    519       D->A: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     520    520       L->A: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     521    521       S->A: No effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     522    522       K->A: No effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     523    523       T->A: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     524    524       L->A,T: Induces a strong decrease in
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     525    525       L->A: Induces a strong decrease in enzyme
FT                                activity. {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     525    525       L->T: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     526    526       R->A: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     527    527       K->A: No effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     528    528       P->A: Has weak or no effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     529    529       R->A: No effect.
FT                                {ECO:0000269|PubMed:15632306}.
FT   MUTAGEN     530    530       L->A,T: Induces a strong decrease in
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15632306}.
FT   CONFLICT      8      8       A -> V (in Ref. 4; BAB16887).
FT                                {ECO:0000305}.
SQ   SEQUENCE   530 AA;  57857 MW;  A82CA227B9D5651B CRC64;
     MSRSPQRALP PGALPRLLQA APAAAPRALL PQWPRRPGRR WPASPLGMKV FRRKALVLCA
     GYALLLVLTM LNLLDYKWHK EPLQQCNPDG PLGAAAGAAG GSWGRPGPPP AGPPRAHARL
     DLRTPYRPPA AAVGAAPAAA AGMAGVAAPP GNGTRGTGGV GDKRQLVYVF TTWRSGSSFF
     GELFNQNPEV FFLYEPVWHV WQKLYPGDAV SLQGAARDML SALYRCDLSV FQLYSPAGSG
     GRNLTTLGIF GAATNKVVCS SPLCPAYRKE VVGLVDDRVC KKCPPQRLAR FEEECRKYRT
     LVIKGVRVFD VAVLAPLLRD PALDLKVIHL VRDPRAVASS RIRSRHGLIR ESLQVVRSRD
     PRAHRMPFLE AAGHKLGAKK EGVGGPADYH ALGAMEVICN SMAKTLQTAL QPPDWLQGHY
     LVVRYEDLVG DPVKTLRRVY DFVGLLVSPE MEQFALNMTS GSGSSSKPFV VSARNATQAA
     NAWRTALTFQ QIKQVEEFCY QPMAVLGYER VNSPEEVKDL SKTLLRKPRL
//
